Literature DB >> 25928337

Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement.

David Goldsmith1, Adrian Covic2, Marc Vervloet3, Mario Cozzolino4, Ionut Nistor5.   

Abstract

This paper reflects the position of the CKD-MBD workgroup, an official working group of ERA-EDTA and of the ERBP advisory board, the official guideline-producing body of ERA-EDTA, on the topic of the use of calcimimetics in patients with CKD stage 5D, as based on two recent meta-analysis.
© The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  calcimimetics

Mesh：

Substances：

Year:  2015        PMID： 25928337     DOI： 10.1093/ndt/gfv050

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


  11 in total

Review 1.  Optimal management of bone mineral disorders in chronic kidney disease and end stage renal disease.

Authors:  Andrew L Lundquist; Sagar U Nigwekar
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-03       Impact factor: 2.894

Review 2.  Calcimimetics versus parathyroidectomy: What is preferable?

Authors:  M Rroji; G Spasovski
Journal:  Int Urol Nephrol       Date:  2018-03-12       Impact factor: 2.370

Review 3.  Surgical management of secondary hyperparathyroidism in chronic kidney disease--a consensus report of the European Society of Endocrine Surgeons.

Authors:  Kerstin Lorenz; Detlef K Bartsch; Juan J Sancho; Sebastien Guigard; Frederic Triponez
Journal:  Langenbecks Arch Surg       Date:  2015-10-02       Impact factor: 3.445

Review 4.  Secondary Hyperparthyroidism: Pathogenesis, Diagnosis, Preventive and Therapeutic Strategies.

Authors:  Mariano Rodríguez Portillo; María E Rodríguez-Ortiz
Journal:  Rev Endocr Metab Disord       Date:  2017-03       Impact factor: 6.514

Review 5.  Vitamin D and Calcimimetics in Cardiovascular Disease.

Authors:  Kenneth Lim; Takayuki Hamano; Ravi Thadhani
Journal:  Semin Nephrol       Date:  2018-05       Impact factor: 5.299

Review 6.  Building on evidence to improve patient care.

Authors:  Evelien Snauwaert; Johan VandeWalle; Evi V Nagler; Wim Van Biesen
Journal:  Pediatr Nephrol       Date:  2016-12-09       Impact factor: 3.714

Review 7.  Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism.

Authors:  Jordi Bover; Pablo Ureña; César Ruiz-García; Iara daSilva; Patricia Lescano; Jacqueline del Carpio; José Ballarín; Mario Cozzolino
Journal:  Clin J Am Soc Nephrol       Date:  2015-07-29       Impact factor: 8.237

8.  Effect of extended hours dialysis on markers of chronic kidney disease-mineral and bone disorder in the ACTIVE Dialysis study.

Authors:  Zhipeng Zhan; Brendan Smyth; Nigel D Toussaint; Nicholas A Gray; Li Zuo; Janak R de Zoysa; Christopher T Chan; Chenggang Jin; Anish Scaria; Carmel M Hawley; Vlado Perkovic; Meg J Jardine; Ling Zhang
Journal:  BMC Nephrol       Date:  2019-07-12       Impact factor: 2.388

9.  Cinacalcet use and the risk of cardiovascular events, fractures and mortality in chronic kidney disease patients with secondary hyperparathyroidism.

Authors:  Marie Evans; Shona Methven; Alessandro Gasparini; Peter Barany; Kate Birnie; Stephanie MacNeill; Margaret T May; Fergus J Caskey; Juan-Jesus Carrero
Journal:  Sci Rep       Date:  2018-02-01       Impact factor: 4.379

Review 10.  Impact of surgical parathyroidectomy on chronic kidney disease-mineral and bone disorder (CKD-MBD) - A systematic review and meta-analysis.

Authors:  Mugurel Apetrii; David Goldsmith; Ionut Nistor; Dimitrie Siriopol; Luminita Voroneanu; Dragos Scripcariu; Marc Vervloet; Adrian Covic
Journal:  PLoS One       Date:  2017-11-06       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.